LifeSensors is a leader in Ubiquitin Proteasome System (UPS) drug discovery technologies and SUMO Platform for Difficult to Express Proteins. We are pleased to inform you that members of our team will be at Bio International Convention and Biopartnering on June 4-7th 2018 in Boston. BIO International brings biotechnology and pharmaceutical companies together to partner in an effort to solve some of medicines most difficult problems. We are confident that our ubiquitin based technology will be able to help our partners jump-start their drug discovery programs and result in first-in-class drugs. If you are attending BIO International, please contact us to set up a meeting.
Regards
Mark Tingey
Business Development
LifeSensors, Inc.
(610) 644 – 8845 ext: 310
bd@lifesensors.com
www.lifesensors.com
271 Great Valley Parkway
Malvern, PA 19355
Attending BIO 2018? Contact Us to set up a meeting.
With ubiquitin’s core functions in plants and animals being so similar it has long been speculated that insights into the
The functional consequences of protein polyubiquitination are determined by the type of ubiquitin chain assembled on the substrate. Among the
While direct K-RAS inhibitors represent a major therapeutic advance, targeting this oncoprotein remains a significant challenge due to limited druggable
Pan-selective Tandem Ubiquitin-Binding Entities (TUBEs) are engineered, high-affinity reagents composed of multiple ubiquitin-associated (UBA) domains that bind polyubiquitin chains with
LifeSensors is pleased to bring attention to some of our academic colleagues who have used our products in the past
Different lysines on ubiquitin are involved in forming different ubiquitin chains, with K48-linked chains primarily signaling for proteasomal degradation, while
With ubiquitin’s core functions in plants and animals being so similar it has long been speculated that insights into the
The functional consequences of protein polyubiquitination are determined by the type of ubiquitin chain assembled on the substrate. Among the
While direct K-RAS inhibitors represent a major therapeutic advance, targeting this oncoprotein remains a significant challenge due to limited druggable
Pan-selective Tandem Ubiquitin-Binding Entities (TUBEs) are engineered, high-affinity reagents composed of multiple ubiquitin-associated (UBA) domains that bind polyubiquitin chains with
LifeSensors is pleased to bring attention to some of our academic colleagues who have used our products in the past
Different lysines on ubiquitin are involved in forming different ubiquitin chains, with K48-linked chains primarily signaling for proteasomal degradation, while
